Adam Feuerstein

Last updated

Adam Feuerstein is an American blogger and columnist covering the biotechnology sector.

Contents

Education

Adam Feuerstein completed a bachelor's degree in political science at Emory University. [1]

Career

Feuerstein covered business, technology, and commercial real estate for the San Francisco Business Times and the Atlanta Business Chronicle as an assistant managing editor. [1] [2] He later wrote about business software for Upside.com. In March 2001, he joined TheStreet.com. From 2005 to 2006 he worked as a research analyst for a hedge fund before returning to TheStreet. He resigned in May 2017. Feuerstein accepted a position as a national biotechnology columnist at STAT in June 2017. [1]

Feuerstein is known for his style of reporting and his tweets to his large Twitter following. [3] [4] He often shares "unabashed" views on Biotech stock and the Food and Drug Administration. [5]

Related Research Articles

<span class="mw-page-title-main">Biogen</span> Pharmaceutical company

Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide. Biogen operates in Argentina, Brazil, Canada, China, France, Germany, Hungary, India, Italy, Japan, Mexico, Netherlands, Poland, Sweden, and Switzerland.

Feuerstein may refer to:

The pharmaceutical industry in India was valued at an estimated US$42 billion in 2021 and is estimated to reach $130 billion by 2030. India is the world's largest provider of generic medicines by volume, with a 20% share of total global pharmaceutical exports. It is also the largest vaccine supplier in the world by volume, accounting for more than 60% of all vaccines manufactured in the world. Indian pharmaceutical products are exported to various regulated markets including the US, UK, European Union and Canada.

<span class="mw-page-title-main">Celltech</span> Former British-based biotechnology firm

Celltech Group plc was a leading British-based biotechnology business based in Slough. It was listed on the London Stock Exchange and was a constituent of the FTSE 100 Index. Celltech was instrumental in changing the UK's system of technology transfer from research to business, and in creating the biotechnology industry.

<span class="mw-page-title-main">Thermo Fisher Scientific</span> Provisioner of scientific consumables, equipment, and services

Thermo Fisher Scientific Inc. is an American supplier of analytical instruments, life sciences solutions, specialty diagnostics, laboratory, pharmaceutical and biotechnology services. Based in Waltham, Massachusetts, Thermo Fisher was formed through the merger of Thermo Electron and Fisher Scientific in 2006. Thermo Fisher Scientific has acquired other reagent, consumable, instrumentation, and service providers, including Life Technologies Corporation (2013), Alfa Aesar (2015), Affymetrix (2016), FEI Company (2016), BD Advanced Bioprocessing (2018), and PPD (2021).

Randal J. Kirk is an American businessman and investor in pharmaceuticals and biotechnology. Kirk was the chairman and chief executive officer of Intrexon, a biotechnology company, until 2020. Kirk started as a lawyer, but is best known for his investments in pharmaceutical and biotech companies. In addition to high-profile sales of New River Pharmaceuticals, Inc., and Clinical Data, Inc, Kirk also founded investment firm Third Security, LLC, and has held board seats with biotech companies, such as Scios, Inc. He is a billionaire.

Christoph Westphal is an American biomedical businessman.

<span class="mw-page-title-main">Martin Shkreli</span> American financial criminal and businessman (b. 1983)

Martin Shkreli is an American financial criminal and businessman. Shkreli is the co-founder of the hedge funds Elea Capital, MSMB Capital Management, and MSMB Healthcare, the co-founder and former CEO of pharmaceutical firms Retrophin and Turing Pharmaceuticals, and the former CEO of start-up software company Gödel Systems, which he founded in August 2016.

<span class="mw-page-title-main">Joseph Jimenez</span>

Joseph Jimenez is the former CEO of the Swiss pharmaceutical company Novartis.

Arie S. Belldegrun, FACS, is an Israeli-American urologic oncologist, billionaire businessman and investor.

<span class="mw-page-title-main">Geoffrey von Maltzahn</span> American inventor

Geoffrey von Maltzahn is an American biological engineer and businessman in the biotechnology and life sciences industry who has founded a number of companies including Indigo Agriculture, Sana Biotechnology, Kaleido Biosciences, Seres Therapeutics, Axcella Health, Generate Biomedicines and Tessera Therapeutics. He has over 200 bioengineering and biotechnology patents and applications.

<span class="mw-page-title-main">Moderna</span> American biotechnology company

Moderna, Inc. is a pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA (mRNA) to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern".

<span class="mw-page-title-main">NF (rapper)</span> American rapper, singer, songwriter, and record producer (born 1991)

Nathan John Feuerstein, known by his initials NF, is an American rapper, singer, songwriter, and record producer. He has released two EPs, I'm Free (2012), and a self-titled EP in 2014 with Capitol CMG. His second and first major-label studio album, Mansion, was released on March 31, 2015. His third studio album, Therapy Session, was released on April 22, 2016, and peaked at number 12 on the US Billboard 200. His albums have earned several accolades, some of which include: the Gospel Music Association Dove Award for Rap/Hip Hop Album of the Year.

<span class="mw-page-title-main">Sio Gene Therapies</span> American pharmaceutical company

Sio Gene Therapies, Inc. was a clinical-stage pharmaceutical company that developed gene therapies to treat neurological disorders. The company was headquartered in New York City and was incorporated in Basel, Switzerland. The company was founded by former hedge fund analyst and 2024 Republican Party presidential primary candidate Vivek Ramaswamy in October 2014 as a wholly owned subsidiary of Roivant Sciences, which was itself founded in May 2014.

<span class="mw-page-title-main">Henri Termeer</span>

Henri A. Termeer was a Dutch biotechnology executive and entrepreneur who is considered a pioneer in corporate strategy in the biotechnology industry for his tenure as CEO at Genzyme. Termeer created a business model adopted by many others in the biotech industry by garnering steep prices— mainly from insurers and government payers— for therapies for rare genetic disorders known as orphan diseases that mainly affect children. Genzyme uses biological processes to manufacture drugs that are not easily copied by generic-drug makers. The drugs are also protected by orphan drug acts in various countries which provides extensive protection from competition and ensures coverage by publicly funded insurers. As CEO of Genzyme from 1981 to 2011, he developed corporate strategies for growth including optimizing institutional embeddedness nurturing vast networks of influential groups and clusters: doctors, private equity, patient-groups, insurance, healthcare umbrella organizations, state and local government, and alumni. Termeer was "connected to 311 board members in 17 different organizations across 20 different industries" He has the legacy of being the "longest-serving CEO in the biotechnology industry.

Biotechnology in India is a sunrise sector within the Indian economy. Agencies of the Government of India concerned with the biotechnology industry include the Department of Biotechnology and the proposed Biotechnology Regulatory Authority of India. As of 2022, the sector is valued at $80 billion. Biotechnology in India is in a growth phase and the sector is expected to be valued at $150 billion by 2025 and surpass $300 billion in value by 2030.

The Biotechnology Innovation Organization (BIO) is the largest advocacy association in the world representing the biotechnology industry. It was founded in 1993 as the Biotechnology Industry Organization from a merger of the Industrial Biotechnology Association (IBA) and the Association of Biotechnology Companies (ABC), and changed its name to the Biotechnology Innovation Organization on January 4, 2016. Biotechnology Innovation Organization serves more than 1,100 biotechnology firms, research schools, state biotechnology centers and related associations in the United States and in more than 30 other countries.

Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.

Arrakis Therapeutics is a biopharmaceutical company developing oral medicines that target RNA to treat a range of diseases. The company is based in Waltham, Massachusetts, and was founded in 2015 by Jennifer Petter, now the company's Chief Innovation Officer. In October 2016, Michael Gilman, a former Biogen executive, was named CEO.

<span class="mw-page-title-main">Jeffrey Leiden</span> CEO of biotechnology company

Jeffrey Leiden is an American businessman who is the executive chairman of Vertex Pharmaceuticals, a biotechnology company based in Boston, Massachusetts. He was initially appointed to the board of directors of the company in 2009 and was CEO and president from February 2012 to March 2020.

References

  1. 1 2 3 Roush, Chris (May 30, 2017). "TheStreet's Feuerstein leaving for STAT". Talking Biz News. Retrieved 2018-11-23.
  2. "Adam Feuerstein Preps for Move to STAT". Cision . June 1, 2017. Retrieved 2018-11-23.
  3. Robbins, Rebecca (May 2, 2016). "Is Adam Feuerstein the most feared man in biotech?". STAT . Retrieved 2018-11-23.
  4. Valleskey, Brianna (November 14, 2014). "How Adam Feuerstein Follows The Biotech Sector". Benzinga. Retrieved 2018-11-23 via Yahoo.
  5. Schifrin, Matthew (2010-10-01). The Warren Buffetts Next Door: The World's Greatest Investors You've Never Heard Of and What You Can Learn From Them. John Wiley & Sons. p. 88. ISBN   9780470915301.